| Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation RD Lopes, G Heizer, R Aronson, et al. N Engl J Med doi: 10.1056/NEJMoa1817083 380 (16), 1509-1524, 2019 | 1088 | 2019 |
| Rivaroxaban in Peripheral Artery Disease after Revascularization MP Bonaca, RM Bauersachs, SS Anand, et al. N Engl J Med 382, 1994-2004, 2020 | 735 | 2020 |
| Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease WR Hiatt, FGR Fowkes, G Heizer, et al., ... The New England Journal of Medicine, 32-40, 2017 | 662 | 2017 |
| Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients AT Cohen, RA Harrington, SZ Goldhaber, et al., ... The New England Journal of Medicine, 534-544, 2016 | 503 | 2016 |
| Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients SE Nissen, AM Lincoff, D Brennan, et al. NEW ENGLAND JOURNAL OF MEDICINE, 2023 | 340 | 2023 |
| Ticagrelor in Patients with Stable Coronary Disease and Diabetes PG Steg, DL Bhatt, T Simon, et al. New England Journal of Medicine, Pages: 1309-1320, 2019 | 333 | 2019 |
| Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness AC Spyropoulos, W Ageno, GW Albers, et al. N Engl J Med. DOI: 10.1056/NEJMoa1805090 379 (12), 1118-1127, 2018 | 272 | 2018 |
| Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo … DL Bhatt, PG Steg, SR Mehta, LA Leiter, T Simon, K Fox, C Held, ... The Lancet 394 (10204), 1169-1180, 2019 | 202 | 2019 |
| Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD GM Chertow, PE Pergola, YMK Farag, et al. NEW ENGLAND JOURNAL OF MEDICINE 384 (17), 1589-1600, 2021 | 159 | 2021 |
| Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease WS Jones, I Baumgartner, WR Hiatt, et al. Circulation, 241-250, 2016 | 128 | 2016 |
| Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective … S Windecker, RD Lopes, T Massaro, et al. Circulation, 1921–1932, 2019 | 86 | 2019 |
| Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill … CM Gibson, G Chi, R Halaby, et al. Circulation, 648-655, 2017 | 70 | 2017 |
| The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial CM Gibson, R Halaby, S Korjian, et al. American Heart Journal, 93-100, 2017 | 57 | 2017 |
| Ferric Carboxymaltose in Heart Failure with Iron Deficiency RJ Mentz, J Garg, FW Rockhold, et. al. NEW ENGLAND JOURNAL OF MEDICINE 389 (11), 975-986, 2023 | 53 | 2023 |
| Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy CM Gibson, S Korjian, G Chi, et al. J Am Heart Assoc., 2017 | 49 | 2017 |
| Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization I Baumgartner, L Norgren, FGR Fowkes, et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 72 (14), Pages: 1563-1572, 2018 | 44 | 2018 |
| Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial RM Bauersachs, M Szarek, M Brodmann, et. al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 78 (4), 317-326, 2021 | 40 | 2021 |
| Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial L Norgren, MR Patel, WR Hiatt, et al. European Journal of Vascular end Endovascular Surgery, Pages 109–117, 2018 | 40 | 2018 |
| Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial JS Berger, BL Abramson, RD Lopes, et al. Vascular Medicine, 523-530, 2018 | 38 | 2018 |
| Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency Rationale and Design RJ Mentz, AP Ambrosy, JA Ezekowitz, et al. CIRCULATION-HEART FAILURE 14 (5), 596-603, 2021 | 34 | 2021 |
Valerii Ivanov Валерій ІвановNational Pirogov Memorial Medical University, Vinnytsya Вінницький національний медичний університетПідтверджена електронна адреса в vnmu.edu.ua
